Terminated EARLY_PHASE1 INTERVENTIONAL 2-arm
NCT06888518
Multistrain Probiotics Against Bacterial Vaginosis
Building Up the Vaginal Flora Using Multistrain Probiotics in Patients with Bacterial Vaginosis
Sponsor: Institut AllergoSan Pharma GmbH
Conditions
Bacterial Vaginosis (BV)
Interventions
OMNi-BiOTiC® FLORA plus+ antibiotic
Updated 1 time since 2025 Last updated: Mar 20, 2025 Started: Dec 12, 2022 Primary completion: Jun 3, 2024 Completion: Jun 3, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Terminated
poor recruitment
Listed as NCT06888518, this EARLY_PHASE1 trial focuses on Bacterial Vaginosis (BV) and remains terminated or withdrawn. Sponsored by Institut AllergoSan Pharma GmbH, it has been updated 1 time since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
1 version recorded Terminated — EARLY_PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Institut AllergoSan Pharma GmbH
- MEDIZINISCHE UNIVERSITAT GRAZ
- Medical University of Vienna
- Medizinische Universität Innsbruck, OE Clinical Trial Center (Koordinierungszentrum für klinische Studien, KKS)
Data source: Institut AllergoSan Pharma GmbH
For direct contact, visit the study record on ClinicalTrials.gov .